1 Meier. R. et al. “Five-Year Outcome From a Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer.” International Journal of Radiation Oncology • Biology • Physics, Volume 96, Issue 2, S33 – S34.
2 Fuller D.B., et. al. “5-year outcomes from a prospective multi-institutional trial of heterogeneous dosing stereotactic body radiotherapy (SBRT) for low- and intermediate-risk prostate cancer.” J Clin Oncol 35. 2017; 6S;35.
3 Zelefsky M.J., Chan H et al. “Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.” J Urol 2006; 176:1415-9.
4 Cheung R., Tucker S.L. et al. “Dose-Response Characteristics of Low- and Intermediate-Risk Prostate Cancer Treated with External Beam Radiotherapy.” Int J Radiat Oncol Biol Phys 2005; 61(4): 993-1002.
5 Lawton CA, DeSilvio M, Lee WR, et al. “Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05).” Int J Radiat Oncol Biol Phys 67:39-47, 2007.
6 Taira AV, Merrick GS, Galbreath RW, et al. “Natural history of clinically staged low-and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy.” Int J Radiat Oncol Biol Phys 76:349-54, 2010.
7 Demanes D. J. et al. “High dose rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer.” Int J Radiat Oncol Biol Phys 81(5): 1286-1292, 2011.
8 Michalski JM, Moughan J, Purdy J, et al. “A randomized trial of 79.2 Gy versus 70.2 Gy radiation therapy (RT) for localized prostate cancer.” J Clin Oncol 33(S7): abstr4, 2015.
9 Spratt DE, Pei X, Yamada J, et al. “Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer.” Int J Radiat Oncol Biol Phys 85:686–92, 2013